ARDX
Price
$6.38
Change
+$0.19 (+3.07%)
Updated
Aug 28, 04:59 PM (EDT)
Capitalization
1.49B
63 days until earnings call
CGEN
Price
$1.44
Change
-$0.03 (-2.04%)
Updated
Aug 28, 03:53 PM (EDT)
Capitalization
135.73M
70 days until earnings call
Interact to see
Advertisement

ARDX vs CGEN

Header iconARDX vs CGEN Comparison
Open Charts ARDX vs CGENBanner chart's image
Ardelyx
Price$6.38
Change+$0.19 (+3.07%)
Volume$78.77K
Capitalization1.49B
Compugen
Price$1.44
Change-$0.03 (-2.04%)
Volume$511
Capitalization135.73M
ARDX vs CGEN Comparison Chart in %
Loading...
ARDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARDX vs. CGEN commentary
Aug 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARDX is a Buy and CGEN is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 28, 2025
Stock price -- (ARDX: $6.19 vs. CGEN: $1.47)
Brand notoriety: ARDX and CGEN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARDX: 59% vs. CGEN: 62%
Market capitalization -- ARDX: $1.49B vs. CGEN: $135.73M
ARDX [@Biotechnology] is valued at $1.49B. CGEN’s [@Biotechnology] market capitalization is $135.73M. The market cap for tickers in the [@Biotechnology] industry ranges from $99.27B to $0. The average market capitalization across the [@Biotechnology] industry is $1.84B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARDX’s FA Score shows that 0 FA rating(s) are green whileCGEN’s FA Score has 1 green FA rating(s).

  • ARDX’s FA Score: 0 green, 5 red.
  • CGEN’s FA Score: 1 green, 4 red.
According to our system of comparison, ARDX is a better buy in the long-term than CGEN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARDX’s TA Score shows that 4 TA indicator(s) are bullish while CGEN’s TA Score has 4 bullish TA indicator(s).

  • ARDX’s TA Score: 4 bullish, 3 bearish.
  • CGEN’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, ARDX is a better buy in the short-term than CGEN.

Price Growth

ARDX (@Biotechnology) experienced а +3.34% price change this week, while CGEN (@Biotechnology) price change was +2.08% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.10%. For the same industry, the average monthly price growth was +14.72%, and the average quarterly price growth was +30.35%.

Reported Earning Dates

ARDX is expected to report earnings on Oct 30, 2025.

CGEN is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+2.10% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARDX($1.49B) has a higher market cap than CGEN($136M). ARDX YTD gains are higher at: 22.091 vs. CGEN (-3.922). CGEN has higher annual earnings (EBITDA): -19.81M vs. ARDX (-29.19M). ARDX has more cash in the bank: 238M vs. CGEN (93.9M). CGEN has less debt than ARDX: CGEN (2.97M) vs ARDX (207M). ARDX has higher revenues than CGEN: ARDX (386M) vs CGEN (22.1M).
ARDXCGENARDX / CGEN
Capitalization1.49B136M1,099%
EBITDA-29.19M-19.81M147%
Gain YTD22.091-3.922-563%
P/E RatioN/A64.00-
Revenue386M22.1M1,747%
Total Cash238M93.9M253%
Total Debt207M2.97M6,970%
FUNDAMENTALS RATINGS
ARDX vs CGEN: Fundamental Ratings
ARDX
CGEN
OUTLOOK RATING
1..100
2969
VALUATION
overvalued / fair valued / undervalued
1..100
98
Overvalued
74
Overvalued
PROFIT vs RISK RATING
1..100
92100
SMR RATING
1..100
9796
PRICE GROWTH RATING
1..100
3879
P/E GROWTH RATING
1..100
4424
SEASONALITY SCORE
1..100
n/a18

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CGEN's Valuation (74) in the Biotechnology industry is in the same range as ARDX (98). This means that CGEN’s stock grew similarly to ARDX’s over the last 12 months.

ARDX's Profit vs Risk Rating (92) in the Biotechnology industry is in the same range as CGEN (100). This means that ARDX’s stock grew similarly to CGEN’s over the last 12 months.

CGEN's SMR Rating (96) in the Biotechnology industry is in the same range as ARDX (97). This means that CGEN’s stock grew similarly to ARDX’s over the last 12 months.

ARDX's Price Growth Rating (38) in the Biotechnology industry is somewhat better than the same rating for CGEN (79). This means that ARDX’s stock grew somewhat faster than CGEN’s over the last 12 months.

CGEN's P/E Growth Rating (24) in the Biotechnology industry is in the same range as ARDX (44). This means that CGEN’s stock grew similarly to ARDX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARDXCGEN
RSI
ODDS (%)
Bearish Trend 2 days ago
79%
Bullish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
80%
Bullish Trend 2 days ago
78%
Momentum
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 8 days ago
88%
Bullish Trend 2 days ago
80%
Declines
ODDS (%)
N/A
Bearish Trend 8 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
89%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
ARDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BPOSY2.51N/A
N/A
Bpost SA
TLKMF0.17N/A
N/A
PT Telekomunick
RTGC0.36N/A
N/A
Ridder Titan Genesis Corp.
CSASF19.89N/A
N/A
Credit Saison Co., Ltd.
PSRHF0.33-0.01
-2.74%
PULSAR HELIUM INC.

CGEN and

Correlation & Price change

A.I.dvisor indicates that over the last year, CGEN has been loosely correlated with NURPF. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if CGEN jumps, then NURPF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CGEN
1D Price
Change %
CGEN100%
+1.38%
NURPF - CGEN
46%
Loosely correlated
N/A
BDTX - CGEN
44%
Loosely correlated
-1.03%
ASPHF - CGEN
41%
Loosely correlated
N/A
ORMP - CGEN
40%
Loosely correlated
+4.25%
ROIV - CGEN
40%
Loosely correlated
+1.27%
More